In the context of BCR::ABL1-independent pathways, combination therapies that target both BCR::ABL1 and alternative survival pathways have the potential to eliminate leukaemic stem cells and sensitize progenitor cells, improving the treatment of CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.